Opportunity for Evaluation of Pharmaceutical Products – Antituberculosis Medicines
13 February 2023
The Global Fund invites manufacturers of pharmaceutical products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for pharmaceutical products (ERP). This evaluation will focus particularly on Antituberculosis medicines:
- Clofazimine 50 mg, tablet or dispersible tablet
- Rifapentine 150 mg, dispersible tablet (preferably functionally scored)
Detailed information about the review process and submission requirements can be found on the Expert Review Panel page.
This is an open invitation and the submission of an expression of interest is possible at any time.
Invitation to Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English